Syndax Pharmaceuticals, Inc. — Revenue by Fiscal Year
11 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/69df7ecb-b3d3-47a4-aecc-b8da79eaaae7/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $172.4M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-076536 |
| FY 2024 | $23.7M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-030394 |
| FY 2023 | $0 | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-021253 |
| FY 2022 | $0 | 2022-01-01 – 2022-12-31 | evidence 0000950170-24-021253 |
| FY 2021 | $139.7M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-008112 |
| FY 2020 | $1.5M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-012607 |
| FY 2019 | $1.5M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-009016 |
| FY 2018 | $1.5M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-006772 |
| FY 2017 | $2.1M | 2017-01-01 – 2017-12-31 | evidence 0001564590-19-006772 |
| FY 2016 | $1.2M | 2016-01-01 – 2016-12-31 | evidence 0001564590-19-006772 |
| FY 2015 | $627.0k | 2015-01-01 – 2015-12-31 | evidence 0001193125-17-081863 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Syndax Pharmaceuticals, Inc. — all facts · Net Income · Operating Income